ACADIA Pharmaceuticals Inc. ACAD
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) is a CNS/neurology/psychiatry drug developer. Its lead program, NUPLAZID (pimavanserin), is in Phase 3 for Hallucinations and delusions associated with Parkinson's disease psychosis. Its next catalyst on record is Remlifanserin (LBDP): Phase 2 data readout (Q4 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Remlifanserin (LBDP) — Phase 2 data readout (Q4 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NUPLAZID (pimavanserin) | Parkinson's disease psychosis | small molecule | Approved |
| DAYBUE (trofinetide) | Rett syndrome | protein/peptide | Approved |
| DAYBUE STIX (trofinetide) | Rett syndrome | protein/peptide | Approved |
| DAYBU (trofinetide) | Neurobehavioral symptoms of Rett syndrome (EU approval) | protein/peptide | Approved |
| Remlifanserin | Alzheimer's disease psychosis | small molecule | Phase 3 |
| Remlifanserin | Lewy Body Dementia Psychosis | small molecule | Phase 2 |
| ACP-211 | Major depressive disorder | small molecule | Phase 2 |
| ACP-711 | Essential tremor | small molecule | Phase 1 |
| ACP-271 | Not specified | small molecule | Phase 1 |
Recent results and decisions
- Nov 4, 2026positive Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis showed consistent efficacy trends at the 60 mg dose across all four psychosis scales and favorable safety and tolerability profile, supporting Phase 3 development.
Announced Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis, with consistent efficacy trends at the 60 mg dose across all four psychosis scales that were assessed for the full study population and a favorable safety and tolerability pro
Filing - Nov 4, 2026positive Phase 3 study of trofinetide in Rett syndrome in Japan completed with results consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing.
Completed the Phase 3 study of trofinetide in Rett syndrome in Japan, with results consistent with the LAVENDER Phase 3 study and supportive of a planned regulatory filing
Filing - Sep 24, 2026missed Phase 2 RADIANT narrowly missed primary endpoint SAPS-H+D at 60 mg (-12.6 vs -10.4 placebo, p=0.0603); key secondary CGI-S-ADP nominal p=0.0077; Phase 3 to continue with 30 mg arm removed.
Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.